Atara Biotherapeutics Inc (NAS:ATRA)
$ 0.63 0.025 (4.13%) Market Cap: 75.86 Mil Enterprise Value: 82.97 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Atara Biotherapeutics Inc at Cowen HealthCare Conference Transcript

Mar 02, 2020 / 09:10PM GMT
Release Date Price: $13.08 (+7.65%)
Phil Nadeau
Cowen and Company, LLC - Managing Director, Health Care - Biotechnology

Good afternoon. Welcome once again to Cowen and Company's 40th Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen and Company. And it's my pleasure to moderate a fire-side chat with Atara Biotherapeutics.

We're happy to have Pascal Touchon, the President and CEO, here with us today. Pascal, maybe you could start by giving a brief state of the company overview, what are the strengths and challenges of Atara today.

Pascal Touchon
Atara Biotherapeutics Inc. - President and CEO

Thank you, Phil, and good to be here with you today. Clearly, for the 2019 has been a very busy year for Atara. We deliver on those expectations but 2020 is going to be very important year.

We have very clear milestones [to deliver] upon. And the way to look at that around today that we have diversified pipeline adding two programs at clinical stage; one in stage three, one in stage 1B, one in oncology, one in autoimmune disease in (inaudible)

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot